Print Friendly Page

Protocol No. BMTCTN1702

Principal Investigator Juckett, Mark

Phase N/A

Age Group Both

Scope National

Sponsor Type Externally Peer-Reviewed

Title Clinical Transplant-Related Long-term Outcomes of Alternative Donor Allogeneic Transplantation (CTRL-ALT-D)

Objective The main goal of this study is to see if there is a difference in how people do if they are very likely or very unlikely to find an HLA-matched unrelated donor. We also want to see:
  • Barriers patients and their doctors face when trying to get a transplant
  • How many of the patients in this study get a transplant
  • How well patients do after having a transplant depending on the type of donor they use
    We will also ask about your overall health, and how well you can do your everyday activities (quality of life), if you:
  • Have AML or ALL in first remission (no signs of the disease) OR Have early stage MDS
    AND
  • Receive transplant from a matched unrelated donor or half-matched family member
  • Have specific types of conditioning regimen and graft-versus-host disease (GVHD) prophylaxis

  • Treatment NA

    Description Clinical Transplant-Related Long-term Outcomes of Alternative Donor Allogeneic Transplantation

    Key Eligibility
  • Patients of all ages with AML, ALL, MDS, NHL, HL, AA or SCD are eligible
  • Patients must be considered suitable allogeneic hematopoietic cell transplantation (HCT) candidates based on available medical history, physical examination, and laboratory tests
  • Specific testing for organ function is not required for eligibility but, if available, these tests should be used to judge transplant suitability
  • Centers must confirm their intention both to follow the recommended search algorithm and to perform the transplant within the next 6 months if a suitable donor is identified
  • Patients who consent are considered evaluable once the center determines no suitable HLA-matched or 1 antigen mismatched related donor is available (center will also confirm that the patient is still considered a transplant candidate)
    EXCLUSION: Patients with the following will be ineligible for enrollment onto this study:
  • Prior allogeneic HCT (prior autologous transplant is allowed)
  • Previous formal unrelated donor search

  • Applicable Disease Sites Hematologic cancers, other; Leukemia; Lymphoma

    Status Open

    Participating Institutions UW Hospital and Clinics